Trabectedin has also been shown to alter the DNA repair genes including BRCA1 (breast cancer type 1 susceptibility gene) and BRCA2 (breast cancer type 2 susceptibility gene), which launches new perspectives as a chemotherapy option for patients with mutated ovarian and breast cancer (BC) 48. Here, BRCA2 is linked to breast cancer.